Pilot Randomized Controlled Trial of a Novel Smoking Cessation App Designed for Individuals With Co-Occurring Tobacco Use Disorder and Serious Mental Illness
Nicotine & Tobacco Research · 24.08.2020 · 22 (9) · 1533-1542
DOI: 10.1093/ntr/ntz202 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nicotine & Tobacco Research, online erschienen am 31.10.2019. Verfasst von Roger Vilardaga und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC. Hauptthemen laut MEDLINE: Behavior Therapy. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, National Institute on Drug Abuse.
Abstract (Originalsprache)
Introduction
High rates of tobacco use among people with serious mental illness (SMI), along with their unique needs, suggest the importance of developing tailored smoking cessation interventions for this group. Previous early-phase work empirically validated the design and content of Learn to Quit, a theory-based app designed for this population.
Methods
In a pilot randomized controlled trial, we compared the feasibility, acceptability, and preliminary efficacy of Learn to Quit versus QuitGuide, an app designed for the general population. All participants received nicotine replacement therapy and technical assistance. Daily smokers with SMI (N = 62) participated in the trial with outcomes assessed at weeks 4, 8, 12, and 16.
Results
Compared to QuitGuide, Learn to Quit participants had similar number of days of app use (34 vs. 32, p = .754), but larger number of app interactions (335 vs. 205; p = .001), longer durations of app use (4.24 hrs. vs. 2.14 hrs; p = .044), and higher usability scores (85 vs. 79, p = .046). At week 16, Learn to Quit led to greater reductions in cigarettes per day (12.3 vs. 5.9 for QuitGuide; p = 0.10). Thirty-day point prevalence abstinence was verified in 12% of Learn to Quit participants versus 3% of QuitGuide participants (odds ratio = 3.86, confidence interval = 0.41 to 36, p = .239). Changes in psychiatric symptoms and adverse events were not clinically significant between conditions.
Conclusions
This pilot trial provides strong evidence of Learn to Quit’s usability, feasibility, and safety. Preliminary evidence suggests the app may be efficacious. A randomized controlled efficacy trial is needed to test the app in a larger sample of smokers with SMI.
Implications
This study suggests that the Learn to Quit app is a feasible approach to deliver smoking cessation treatment in patients with co-occurring tobacco use disorder and SMI. This means that, if found efficacious, this technology could be used to deploy smoking cessation treatment to larger segments of this population, hence improving public health. Therefore, a randomized controlled trial should be conducted to examine the efficacy of this digital intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC.
Förderung
- NIDA NIH HHS
- National Institute on Drug Abuse
Zitieren
APA
Vilardaga, R., Rizo, J., Palenski, P. E., Mannelli, P., Oliver, J. A., & Mcclernon, F. J. (2020). Pilot Randomized Controlled Trial of a Novel Smoking Cessation App Designed for Individuals With Co-Occurring Tobacco Use Disorder and Serious Mental Illness. Nicotine & Tobacco Research, 22(9), 1533-1542. https://doi.org/10.1093/ntr/ntz202
Vancouver
Vilardaga R, Rizo J, Palenski PE, Mannelli P, Oliver JA, Mcclernon FJ. Pilot Randomized Controlled Trial of a Novel Smoking Cessation App Designed for Individuals With Co-Occurring Tobacco Use Disorder and Serious Mental Illness. Nicotine & Tobacco Research. 2020;22(9):1533-1542. doi:10.1093/ntr/ntz202
BibTeX
@article{Vilardaga2020,
author = {Vilardaga, Roger and Rizo, Javier and Palenski, Paige E and Mannelli, Paolo and Oliver, Jason A and Mcclernon, Francis J},
title = {Pilot Randomized Controlled Trial of a Novel Smoking Cessation App Designed for Individuals With Co-Occurring Tobacco Use Disorder and Serious Mental Illness},
journal = {Nicotine & Tobacco Research},
year = {2020},
volume = {22},
number = {9},
pages = {1533--1542},
doi = {10.1093/ntr/ntz202}
}
EUVIMED